Discover how the S&P 500 Index performed in 2024 and what that could mean for the first quarter of 2025 according to Barclays ...

Investment firm Barclays laid out its thoughts for the technology space in 2025 in a research note on Thursday, covering ...

Amazon’s satellite broadband initiative, Project Kuiper, shows huge potential. Find out why AMZN stock could thrive with a ...

Barclays Plc’s Stephen Dainton is preparing for a wave of dealmaking this year as more US companies have been buoyed by ...

Barclays PLC BARC shares inched down 0.26% to £2.65 Wednesday, on what proved to be an all-around positive trading session ...

Emmanuel Cau, head of European equity strategy at Barclays, weighs in on the outlook for European stocks in 2025.

Barclays PLC BARC shares slid 2.60% to £2.66 Tuesday, on what proved to be an all-around grim trading session for the stock ...

China, the global growth engine for the last 20 years, now boasts lower long-term bond yields than Japan, the former poster ...

BTS member J-Hope reveals his first-ever solo tour, hitting venues in 2025 in North America and Asia for Hope on the Stage ...

Barclays analyst Peter Lawson maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $105.00.

In a report released today, Seth Sigman from Barclays maintained a Hold rating on Five Below (FIVE – Research Report), with a price target of ...

On Wednesday, Barclays PLC (BCS) stock saw a decline, ending the day at $13.19 which represents a decrease of $-0.06 or -0.45% from the prior close of $13.25. The stock opened at $13.01 and touched a ...